Company profile: Beckley Psytech
1.1 - Company Overview
Company description
- Provider of psychedelic medicine R&D focused on mental health, developing investigational therapies including BPL-003, a synthetic intranasal 5-MeO-DMT for Treatment Resistant Depression and Alcohol Use Disorder, and ELE-101, an intravenous psilocin for Major Depressive Disorder; exploring the therapeutic potential of psilocybin and other compounds.
Products and services
- ELE-101: An investigational intravenous psilocin product being developed for the treatment of Major Depressive Disorder, formulated for clinical infusion administration
- BPL-003: A synthetic, investigational intranasal 5-MeO-DMT product being investigated for Treatment Resistant Depression and Alcohol Use Disorder, engineered for intranasal delivery
- Psychedelic medicine R&D and integration: Explores therapeutic potential of psilocybin and other compounds for mental health, envisioning clinically validated medicine integration into contemporary medical practice.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Beckley Psytech
MicroTransponder
HQ: United States
Website
- Description: Provider of neurostimulation medical devices and therapies to treat neurological diseases, including the Vivistim Paired VNS System for post-stroke arm and hand motor recovery, the Serenity System for tinnitus, and the Model 1001 implantable vagus nerve lead. Offers neurostimulation approaches for PTSD, obsessive disorders, phobias, addiction, and motor function improvement.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MicroTransponder company profile →
Vivoryon Therapeutics
HQ: Germany
Website
- Description: Provider of biopharmaceutical R&D and clinical development focused on small molecule medicines for Alzheimer’s disease and cancer, including varoglutamstat (QPCT inhibitor, Phase 2) and a portfolio of QPCT/L inhibitors, supported by a comprehensive clinical program. Holds a strategic licensing partnership with Simcere for varoglutamstat and a preclinical monoclonal N3pE‑antibody in Greater China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivoryon Therapeutics company profile →
MapLight Therapeutics
HQ: United States
Website
- Description: Provider of a discovery platform using optogenetics, STARmap, and transcriptomics to identify neural circuits and develop therapeutics for brain disorders, including ML-004 for Autism Spectrum Disorder (Phase 2), and candidates for schizophrenia (M1/M4 muscarinic), Alzheimer’s disease psychosis, and Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MapLight Therapeutics company profile →
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
Prestwick Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic pharmaceutical drugs for chronic central nervous system diseases, offering products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea. Founded in 2002 and based in Washington, District of Columbia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prestwick Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Beckley Psytech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Beckley Psytech
2.2 - Growth funds investing in similar companies to Beckley Psytech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Beckley Psytech
4.2 - Public trading comparable groups for Beckley Psytech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →